ADVOCATE. CONNECT. INNOVATE.

Bulletin, Member News

Shifting CAR-TS into a Higher Gear

Original Article Posted on Evaluate

LONDON, BOSTON, TOKYO (June 3, 2016) — Chimeric antigen receptor T cell (CAR-T) therapy has indisputably become one of the industry’s hottest topics and the next 18 months could see the first CAR-T drugs filed for US approval. But behind the excitement for all things CAR-T lie a number of obstacles in their path to approval.

In its second deep-dive into the CAR-T space EP Vantage explores how much of an advantage it will be for to be the first company to achieve approval in a market that has never been tested and the ability to charge premium pricing can only be guessed at.

Read More